Vimarsana
Biggest News Aggregation in the World

Page 2 - Dose Escalation Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dose Escalation Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dose Escalation Study Today - Breaking & Trending Today

Coherus Announces Presentation at the 2024 American Society - Vimarsana News

Coherus Announces Presentation at the 2024 American Society

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of...

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the ... - Vimarsana News

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the ...

Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data

Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-inf - Vimarsana News

Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-inf

KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical ne...

TRYP THERAPEUTICS ANNOUNCES SIGNIFICANT MILESTONE IN ITS CLINICAL TRIAL PROGRAM FOR TRP-8803 (IV-INFUSED PSILOCIN) - Vimarsana News

TRYP THERAPEUTICS ANNOUNCES SIGNIFICANT MILESTONE IN ITS CLINICAL TRIAL PROGRAM FOR TRP-8803 (IV-INFUSED PSILOCIN)

, 01/08/2024 / 07:01, EST/EDT - EQS Newswire - Tryp Therapeutics Inc. (Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Canadian Stock Exchange, Nasdaq OTC)KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a...

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript - Vimarsana News

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […]

Source: yahoo.com